我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
30
2 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
1
3.3%
已完成
24
80.0%
尚未招募
招募中
3
10.0%
终止
暂无批准数据
- An experimental malaria vaccine, PfSPZ Vaccine, demonstrated significant protection against parasite infection and clinical malaria for up to two years in healthy Malian adults. - The vaccine also showed promise in protecting women from malaria during pregnancy, with efficacy rates ranging from 49% to 86% in an exploratory analysis. - The trials, supported by the NIH, suggest that preconception immunization with PfSPZ Vaccine could be a new strategy to reduce mortality for women with malaria in pregnancy. - Further research is planned to assess the safety and efficacy of PfSPZ Vaccine administered during pregnancy in larger clinical trials.
